Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Survival, Quality of Life and Self-reported Outcomes of Elderly Patients With Advanced Non-small Cell Lung Cancer Treated With Pembrolizumab (MK-3475) in the First Line Setting

NCT03293680 is registered in ClinicalTrials.gov with Spanish Lung Cancer Group as lead sponsor.

NCT NCT03293680
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03293680 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Survival, Quality of Life and Self-reported Outcomes of Elderly Patients With Advanced Non-small Cell Lung Cancer Treated With Pembrolizumab (MK-3475) in the First Line Setting
Lead sponsor
Spanish Lung Cancer Group
Phase
Phase 2
Overall status
Completed
Start date
January 15, 2017
Completion date
July 15, 2023
Enrollment
83 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer